001     177085
005     20240229133731.0
024 7 _ |a 10.1007/s00401-021-02377-1
|2 doi
024 7 _ |a pmid:34661724
|2 pmid
024 7 _ |a 0001-6322
|2 ISSN
024 7 _ |a 1432-0533
|2 ISSN
024 7 _ |a altmetric:115408114
|2 altmetric
037 _ _ |a DKFZ-2021-02291
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Schmid, Simone
|0 0000-0002-5787-7343
|b 0
245 _ _ |a Genetic and epigenetic characterization of posterior pituitary tumors.
260 _ _ |a Heidelberg
|c 2021
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1679063065_16993
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2021 Dec;142(6):1025-1043
520 _ _ |a Pituicytoma (PITUI), granular cell tumor (GCT), and spindle cell oncocytoma (SCO) are rare tumors of the posterior pituitary. Histologically, they may be challenging to distinguish and have been proposed to represent a histological spectrum of a single entity. We performed targeted next-generation sequencing, DNA methylation profiling, and copy number analysis on 47 tumors (14 PITUI; 12 GCT; 21 SCO) to investigate molecular features and explore possibilities of clinically meaningful tumor subclassification. We detected two main epigenomic subgroups by unsupervised clustering of DNA methylation data, though the overall methylation differences were subtle. The largest group (n = 23) contained most PITUIs and a subset of SCOs and was enriched for pathogenic mutations within genes in the MAPK/PI3K pathways (12/17 [71%] of sequenced tumors: FGFR1 (3), HRAS (3), BRAF (2), NF1 (2), CBL (1), MAP2K2 (1), PTEN (1)) and two with accompanying TERT promoter mutation. The second group (n = 16) contained most GCTs and a subset of SCOs, all of which mostly lacked identifiable genetic drivers. Outcome analysis demonstrated that the presence of chromosomal imbalances was significantly associated with reduced progression-free survival especially within the combined PITUI and SCO group (p = 0.031). In summary, we observed only subtle DNA methylation differences between posterior pituitary tumors, indicating that these tumors may be best classified as subtypes of a single entity. Nevertheless, our data indicate differences in mutation patterns and clinical outcome. For a clinically meaningful subclassification, we propose a combined histo-molecular approach into three subtypes: one subtype is defined by granular cell histology, scarcity of identifiable oncogenic mutations, and favorable outcome. The other two subtypes have either SCO or PITUI histology but are segregated by chromosomal copy number profile into a favorable group (no copy number changes) and a less favorable group (copy number imbalances present). Both of the latter groups have recurrent MAPK/PI3K genetic alterations that represent potential therapeutic targets.
536 _ _ |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312)
|0 G:(DE-HGF)POF4-312
|c POF4-312
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
650 _ 7 |a Brain tumor
|2 Other
650 _ 7 |a Granular cell tumor
|2 Other
650 _ 7 |a Molecular neuropathology
|2 Other
650 _ 7 |a Pituicytoma
|2 Other
650 _ 7 |a Posterior pituitary gland neoplasms
|2 Other
650 _ 7 |a Spindle cell oncocytoma
|2 Other
700 1 _ |a Solomon, David A
|0 0000-0003-4571-7999
|b 1
700 1 _ |a Perez, Eilis
|b 2
700 1 _ |a Thieme, Anne
|0 P:(DE-He78)21f693ba604e9286be3b25068b440d08
|b 3
|u dkfz
700 1 _ |a Kleinschmidt-DeMasters, Bette K
|b 4
700 1 _ |a Giannini, Caterina
|b 5
700 1 _ |a Reinhardt, Annekathrin
|0 P:(DE-He78)856d5c1d0205a79190ed88218ffaf9b2
|b 6
|u dkfz
700 1 _ |a Asa, Sylvia L
|b 7
700 1 _ |a Mete, Ozgur
|b 8
700 1 _ |a Stichel, Damian
|0 P:(DE-He78)d20d08adc992abdb6ccffa1686f1ba17
|b 9
|u dkfz
700 1 _ |a Siewert, Christin
|0 P:(DE-He78)f796c7ad2ee1221e915ff38c15557abd
|b 10
|u dkfz
700 1 _ |a Dittmayer, Carsten
|b 11
700 1 _ |a Hasselblatt, Martin
|b 12
700 1 _ |a Paulus, Werner
|b 13
700 1 _ |a Nagel, Christoph
|b 14
700 1 _ |a Harter, Patrick
|0 P:(DE-He78)b15b56a6ed37417d476470c60c0140ff
|b 15
700 1 _ |a Schittenhelm, Jens
|b 16
700 1 _ |a Honegger, Jürgen
|b 17
700 1 _ |a Rushing, Elisabeth
|b 18
700 1 _ |a Coras, Roland
|b 19
700 1 _ |a Pfister, Stefan M
|0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
|b 20
|u dkfz
700 1 _ |a Buslei, Rolf
|b 21
700 1 _ |a Koch, Arend
|b 22
700 1 _ |a Perry, Arie
|b 23
700 1 _ |a Jones, David T W
|0 P:(DE-He78)551bb92841f634070997aa168d818492
|b 24
|u dkfz
700 1 _ |a von Deimling, Andreas
|0 P:(DE-He78)a8a10626a848d31e70cfd96a133cc144
|b 25
|u dkfz
700 1 _ |a Capper, David
|0 P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c
|b 26
|u dkfz
700 1 _ |a Lopes, M Beatriz
|0 0000-0001-8661-6727
|b 27
773 _ _ |a 10.1007/s00401-021-02377-1
|0 PERI:(DE-600)1458410-4
|n 6
|p 1025-1043
|t Acta neuropathologica
|v 142
|y 2021
|x 1432-0533
909 C O |p VDB
|o oai:inrepo02.dkfz.de:177085
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)21f693ba604e9286be3b25068b440d08
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)856d5c1d0205a79190ed88218ffaf9b2
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)d20d08adc992abdb6ccffa1686f1ba17
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)f796c7ad2ee1221e915ff38c15557abd
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 15
|6 P:(DE-He78)b15b56a6ed37417d476470c60c0140ff
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 20
|6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 24
|6 P:(DE-He78)551bb92841f634070997aa168d818492
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 25
|6 P:(DE-He78)a8a10626a848d31e70cfd96a133cc144
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 26
|6 P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-312
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Funktionelle und strukturelle Genomforschung
|x 0
914 1 _ |y 2021
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2021-01-29
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2021-01-29
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2021-01-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2021-01-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2021-01-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2021-01-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2021-01-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-01-29
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2021-01-29
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ACTA NEUROPATHOL : 2019
|d 2021-01-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2021-01-29
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2021-01-29
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b ACTA NEUROPATHOL : 2019
|d 2021-01-29
920 1 _ |0 I:(DE-He78)BE01-20160331
|k BE01
|l DKTK BE zentral
|x 0
920 1 _ |0 I:(DE-He78)B300-20160331
|k B300
|l KKE Neuropathologie
|x 1
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 2
920 1 _ |0 I:(DE-He78)FM01-20160331
|k FM01
|l DKTK FM zentral
|x 3
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l B062 Pädiatrische Neuroonkologie
|x 4
920 1 _ |0 I:(DE-He78)B360-20160331
|k B360
|l Pediatric Glioma
|x 5
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)BE01-20160331
980 _ _ |a I:(DE-He78)B300-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a I:(DE-He78)FM01-20160331
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a I:(DE-He78)B360-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21